7FD0 image
Entry Detail
PDB ID:
7FD0
Title:
Crystal Structure of human RIPK1 kinase domain in complex with a novel inhibitor
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2021-07-15
Release Date:
2022-01-19
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.26
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Receptor-interacting serine/threonine-protein kinase 1
Chain IDs:A, B
Chain Length:297
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Potent and Selective RIPK1 Inhibitors Targeting Dual-Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis.
Angew.Chem.Int.Ed.Engl. 61 e202114922 e202114922 (2022)
PMID: 34851543 DOI: 10.1002/anie.202114922

Abstact

Sepsis, characterized with high risk of life-threatening organ dysfunction, represents a major cause of health loss and the World Health Organization (WHO) labelled sepsis as the most urgent unmet medical need in 2017. The emerging biological understanding of the role of RIPK1 in sepsis has opened up an exciting opportunity to explore potent and selective RIPK1 inhibitors as an effective therapeutic strategy for SIRS and sepsis therapy. Herein, we have synthesized a class of highly potent dual-mode RIPK1 inhibitors occupying both the allosteric and the ATP binding pockets, exemplified by compound 21 (ZB-R-55) which is about 10-fold more potent than GSK2982772, and exhibits excellent kinase selectivity, good oral pharmacokinetics and good therapeutic effects in the LPS-induced sepsis model, suggesting that compound ZB-R-55 is a highly promising preclinical candidate.

Legend

Protein

Chemical

Disease

Primary Citation of related structures